CannPal Bolsters Research Team with New Elanco Recruit
- CannPal Further Bolsters Research Team with Appointment of US-based, Board Certified, Animal Toxicology Expert Dr Jeffrey Sherman
- CannPal has engaged a second ex-Elanco industry veteran, Dr Jeffrey Sherman, to assist the Company in the development of its cannabis-derived medicines
- Dr Sherman is a diplomat of the American Board of Toxicology and will advise on the toxicological components of current and future product approvals for major regulatory regions such as the US, Europe and Australia
- Dr. Sherman will work closely with Dr Margaret Curtis, who was appointed as CannPal’s Head of Clinical Development and R&D in November, 2017
- Along with his experience in animal health, Dr Sherman brings significant knowledge of the endocannabinoid system to CannPal, having published a number of research papers on the cannabinoid receptors
- This latest appointment builds on CannPal’s strategy of developing a strong network of research partners, consultants, and advisors, with global reach in all major markets
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has further bolstered its research team with the appointment of US-based, board-certified animal health toxicology expert Dr Jeffrey Sherman as a consultant to the Company.
Dr Sherman has been engaged to assist CannPal’s research team in the development of the Company’s cannabis-derived medicines. Dr Sherman will provide assistance and advise the preparation of the toxicological components of the Company’s product dossiers, and manage and conduct, subject to future research agreements, toxicological studies for the Company through third-party research organisations.
Dr Sherman is a diplomat of the American Board of Toxicology who brings valuable expertise to the study of the endo-cannabinoid system, having had his research published in a number of prominent journals.
Dr Sherman will support Dr Margaret Curtis who was appointed as CannPal’s Head of Clinical Development and R&D in 2017. Dr Margaret is also an alumnus of Elanco, where she worked for nearly two decades and held multiple director positions. Dr Curtis has significant experience working with international regulatory authorities, having gained approval for over 20 drugs in over 100 countries.
CannPal’s appointment of Dr Sherman adds a US-based consultant to the Company’s existing strong network of research partners and advisors in Europe and Australia.
Through collaboration with its research partner Klifovet AG, one of Europe’s largest veterinary research organisations, CannPal recently announced that it has been granted Small and Medium-size Enterprise (SME) status with the European Medicines Agency (EMA).
CannPal has also entered into a research partnership with Invetus Limited, Australasia’s largest veterinary organisation, who have been engaged to carry out the initial phases of the clinical program for CPAT-01, the Company’s lead drug candidate. The clinical phase is scheduled to commence next month, with a pharmacokinetic and safety study in the final stages of preparation.
About Dr Sherman
Dr Jeffrey Sherman is a highly experienced board-certified toxicologist specialising in assisting development teams realise their goals on time and on budget. Dr Sherman has extensive experience in drug development, target animal safety, pre-clinical toxicology and risk assessment for excipients and impurities.
He received a veterinary degree at Ohio State University, and following a 20-year career as a veterinarian and practice owner he served as an adjunct professor in anatomy and physiology at the University of California, Davis, during graduate studies in pharmacology and toxicology. After joining Eli Lilly and Company’s (NYSE:LLY) animal health division, Elanco, he served as a Senior Research Scientist and lead toxicologist for multiple regulatory approvals, adding over US$100 million in revenue to Elanco.
While working with Elanco Jeff was also a president of the Comparative and Veterinary Specialty Section of the Society of Toxicology (SOT) and served for a number of years as the VICH reviewer in association with AHI for a number of years until he left Elanco.
In that role Jeff worked with US FDA’s Senior Advisor for Science and Policy and was instrumental in the recent revisions to VICH GL23 for genetic toxicity and the writing and approval of the new acute reference dose VICH GL54.